Kevin Campbell Joins Vita Inclinata As Executive Vice President of Finance

Vita Inclinata (Vita), developer and producer of precision aerospace and industrial stabilization devices, today announced the appointment of Kevin Campbell as Executive Vice President of Finance.

Kevin Campbell is an experienced financial executive with a strong mix of technical, operational, strategic, and commercial finance skills and a history of building, leading, and motivating teams in high-growth, investment-oriented businesses.

Kevin Campbell’s goal at Vita is to create shareholder value by ensuring the company makes the best investment decisions to take advantage of its significant organic and acquisition-related growth opportunities. In addition, he will be focused on scaling the finance and accounting functions to support this rapid growth.

Kevin Campbell said, “I am impressed by Vita’s life-saving technology and its impact within the aerospace and industrial markets and am excited to be part of an organization dedicated to saving lives. My background in driving operational improvements, overseeing capital market and corporate development activities, and building teams will better position Vita for its next growth phase.”

Most recently, Campbell was Senior Vice President of Treasury and Corporate Development at Air Methods, which provides emergency medical services to over 100,000 patients annually in 48 states. In this position, he was responsible for capital and investment management, corporate development, capital market activities, treasury, and investor relations. He also previously served as the Senior Vice President of Corporate Finance at Air Methods where he managed the annual budget, quarterly forecast, and management reporting processes, among other things. Before joining Air Methods, Campbell served as Managing Director at Avondale Partners, a boutique investment bank where he wrote research on publicly-traded companies. He began his career at Greenwich Alternative Investments, where he was responsible for qualitative research on hedge funds, managing three funds that invested in other hedge funds, and the firm’s relationships with its largest institutional investors.

“Kevin Campbell’s leadership experience and ability to position corporate financial systems for notable growth is an outstanding addition to our executive team,” said Caleb Carr, CEO of Vita. “His demonstrated experience financially guiding an aviation medical company to national success parallels Vita’s growth goals. We are eager to benefit from the dividends his experience will bring to our organization.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.